Markets:

Overview

News

Currencies

International

Treasuries

Vanguard U.S. Momentum Factor ETF (NY:VFMO)

207.88 -2.85 (-1.35%)

Streaming Delayed Price Updated: 12:13 PM EST, Feb 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vanguard U.S. Momentum Factor ETF

< Previous 1 2 3 Next >

Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗

February 24, 2026

The biotech company reported statistically significant Phase 3 data for QTORIN gel.

Via Stocktwits

Why Did PDYN Stock Pop Over 10% In Pre-Market Today? ↗

February 03, 2026

The company signed an agreement with a major U.S. defense prime contractor to supply a subsystem that supports missile propulsion.

Via Stocktwits

Topics Artificial Intelligence

Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious? ↗

December 19, 2025

The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Via Stocktwits

Lyft Draws Investor Attention After Wedbush Downgrades Stock Amid Autonomous Vehicle Risks ↗

December 19, 2025

Via Stocktwits

Why Is CorMedix Stock Rising Today? ↗

December 18, 2025

CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study.

Via Stocktwits

Toll Brothers Stock Slides After-Hours On Q4 Miss And Softer Delivery Forecast ↗

December 08, 2025

Via Stocktwits

American Eagle's Gen Z Playbook Is Working — Sydney Sweeney And Travis Kelce Might Only Be The Opening Act ↗

December 03, 2025

Via Stocktwits

Uber In Talks With Getir To Expand Delivery Services In Turkey: Report ↗

November 06, 2025

Via Stocktwits

Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit ↗

December 17, 2025

While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in a study even at its highest dose of 40 mg.

Via Stocktwits

JPMorgan Investment Banking Chief Plans Exit After 45 Years As Bank Ramps Up AI And Braces For $105B Costs: Report ↗

December 15, 2025

According to Grant’s Linkedin profile, he joined the lender in 1980 as an investment banker after graduating from Oxford University and rose to be the global chairman of Investment banking.

Via Stocktwits

Topics Artificial Intelligence Retirement

Palantir CIO Jim Siders To Depart After 12 Years To Head Thrive Capital’s New IT Services Business ↗

December 15, 2025

im Siders said that Shield has an incredible combination of long-term vision, technological expertise, and operational know-how, making it perfect for him at the moment.

Via Stocktwits

Topics Artificial Intelligence

ServiceNow Stock Is Down 5% Today — What’s Weighing On The Shares? ↗

December 15, 2025

KeyBank downgraded ServiceNow to ‘Underweight’ from ‘Sector Weight’ with a price target of $775.

Via Stocktwits

Topics Artificial Intelligence

BHVN Stock Tumbled A Whopping 44% Today – What Did The FDA Letter Say? ↗

November 05, 2025

Via Stocktwits

Broadcom Stock Jumps After Hours As Strong Q4 And Surging AI Chip Demand Drive Upbeat Outlook ↗

December 11, 2025

The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion on the back of strong AI chip demand.

Via Stocktwits

Topics Artificial Intelligence

Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗

December 11, 2025

The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.

Via Stocktwits

Micron To Stop Selling Crucial Consumer Products As It Heightens Focus On Larger Customers ↗

December 03, 2025

The company said that it will continue to ship Crucial products to consumers through the end of February 2026.

Via Stocktwits

Abercrombie & Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum ↗

November 28, 2025

Barclays raised its price target on Abercrombie & Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly.

Via Stocktwits

Why ANF Stock Is Soaring Before The Bell Today? ↗

November 25, 2025

Abercrombie now expects net sales to grow in the range of 6% to 7% for fiscal year 2025, compared with the prior forecast of 5% to 7% rise.

Via Stocktwits

Micron Stock Draws Investor Attention Following A Price Target Boost From UBS ↗

November 20, 2025

UBS maintained a ‘Buy’ rating on the shares and noted that its recent channel checks indicate "tight" supply conditions persist.

Via Stocktwits

AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial ↗

November 19, 2025

While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios...

Via Stocktwits

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗

November 18, 2025

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

Via Stocktwits

Why Did Scholar Rock Soar 26% Today? ↗

November 14, 2025

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.

Via Stocktwits

Topics Earnings

Uber COO Says Robotaxi Tech Is Largely Ready But Hardware Costs Are Still Too High ↗

November 12, 2025

Uber has partnerships in place with multiple robotaxi companies, including Pony AI, WeRide and Alphabet Inc’s Waymo.

Via Stocktwits

Topics Artificial Intelligence

Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance ↗

November 12, 2025

The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million.

Via Stocktwits

Topics Earnings

2 Vanguard ETFs to Buy Hand Over Fist and 1 to Avoid ↗

November 12, 2025

Low-cost ETFs are excellent ways to build a diversified stock portfolio without incurring high fees.

Via The Motley Fool

Topics ETFs

Fiserv Shares Plunge 44% In Record One-Day Drop As Company Gets Wall Street Downgrades On Leadership Changes, Forecast Cuts ↗

October 29, 2025

Wolfe Research downgraded Fiserv to ‘Peer Perform’ from ‘Outperform,’ according to TheFly, on the heels of the guidance cut that it says "raised structural concerns."

Via Stocktwits

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results ↗

October 29, 2025

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

Via Stocktwits

Fiserv Stock Plunges 32% As New CFO Paul Todd Steps In Amid Leadership Overhaul, Profit Warning ↗

October 29, 2025

Fiserv now expects 2025 adjusted earnings per share to come between $8.50 and $8.60, down from the previous forecast of $10.15 to $10.30.

Via Stocktwits

Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy ↗

October 23, 2025

CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months.

Via Stocktwits

Arcturus Therapeutics Stock Plunges Over 57% Today: What’s Causing The Sell-Off? ↗

October 22, 2025

The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.

Via Stocktwits

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.